Hypothesis

Overexpressing the nuclear-encoded mitochondrial protease LONP1 shifts intracellular competition in favor of wild-type mitochondria by selectively degrading misfolded proteins encoded by mutant mtDNA, thereby reducing the replicative advantage of deletion-bearing genomes and lowering heteroplasmy load in aged tissues.

Mechanistic Rationale

Mitochondrial genomes lacking histones accumulate mutations that impair respiratory chain subunits, leading to misfolded proteins within the matrix. These defective proteins trigger a compensatory upregulation of mitochondrial chaperones and proteases, but the degradation capacity is often insufficient to clear the damage before mutant genomes out-replicate intact ones [2]. LONP1, a nuclear-encoded ATP-dependent protease, degrades oxidized and misfolded matrix proteins and is known to be upregulated during mitochondrial stress [3]. Enhancing LONP1 activity could increase the turnover of deleterious translation products from mutant mtDNA, reducing the metabolic burden they impose and diminishing the selective edge that deletion-bearing mitochondria enjoy [4]. By making the intracellular environment less permissive to mutant genomes, wild-type mitochondria would regain a replicative advantage, leading to a net decline in heteroplasmy over time.

Experimental Design

1. Model: Generate a knock-in mouse model expressing a inducible, mitochondria-targeted LONP1 transgene (Mito‑LONP1) under a doxycycline-responsive promoter, crossed with a mtDNA mutator strain (PolG^D257A) that accumulates deletion mutations with age.
2. Groups: (a) Mutator mice with Mito‑LONP1 induction (treatment), (b) Mutator mice with transgene but no doxycycline (control), (c) Wild‑type littermates with Mito‑LONP1 induction (to assess any off‑target effects), (d) Wild‑type without induction (baseline).
3. Induction: Begin doxycycline at 12 months of age, maintain for 6 months.
4. Readouts:
   • Quantitative PCR for mtDNA deletion load (heteroplasmy) in skeletal muscle, brain, and heart at 0, 3, and 6 months post‑induction.
   • Respirometry (high‑resolution Oxygraph) to measure ATP production and ROS emission.
   • Proteomic analysis of mitochondrial matrix to quantify levels of misfolded proteins and LONP1 substrates.
   • Mitophagy flux assessed via mt‑Keima reporter.
   • Functional assays: grip strength, treadmill endurance, and cognitive testing (novel object recognition).
5. Statistical Plan: Power analysis targeting 80% power to detect a 20% reduction in heteroplasmy (α=0.05). Use two‑way ANOVA with genotype and treatment as factors, followed by Tukey’s post‑hoc test.

Predicted Outcomes

If the hypothesis holds, treatment mice will exhibit a statistically significant decrease in mtDNA deletion heteroplasmy relative to controls, accompanied by improved respiratory capacity, reduced ROS, enhanced mitophagy, and better functional performance. No such improvements are expected in wild‑type mice overexpressing LONP1, indicating that the effect depends on the presence of mutant mtDNA‑derived proteotoxic stress.

Potential Pitfalls and Alternatives

• Over‑degradation risk: Excessive LONP1 activity could impair essential matrix proteins; monitoring of mitochondrial protein homeostasis will clarify safety margins.
• Compensatory pathways: Upregulation of other proteases (e.g., ClpP) might mask effects; measuring their activity will help isolate LONP1’s contribution.
• Delivery limitations: If inducible transgene expression proves leaky, alternative approaches such as AAV‑mediated Mito‑LONP1 delivery in aged mutator mice can be tested.

Falsification would occur if Mito‑LONP1 induction fails to alter heteroplasmy levels or functional outcomes despite verified increases in protease activity, suggesting that nuclear‑encoded quality control alone cannot overcome the replicative advantage of mutant mitochondrial genomes.

[1] https://www.fightaging.org/archives/2024/12/allotopic-expression-of-mitochondrial-gene-atp8-in-mice/ [2] https://www.fightaging.org/archives/2024/09/mutation-in-the-context-of-allotopic-expression-of-mitochondrial-dna/ [3] https://doi.org/10.1038/s41591-018-0166-8 [4] https://doi.org/10.1155/2015/305716 [5] https://exosome-rna.com/supercharged-mitochondrial-vesicles-offer-new-hope-for-mitochondrial-disease-treatment/ [6] https://doi.org/10.1101/2024.06.22.600215 [7] https://pmc.ncbi.nlm.nih.gov/articles/PMC8962324/